Biohaven (BHVN) Competitors

Biohaven (NYSE:BHVN) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Which has more volatility and risk, BHVN or GMAB?

Biohaven has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Do institutionals and insiders hold more shares of BHVN or GMAB?

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 16.0% of Biohaven shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community favor BHVN or GMAB?

Biohaven received 240 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 67.17% of users gave Biohaven an outperform vote while only 62.65% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Biohaven	Outperform Votes 401 67.17%	Underperform Votes 196 32.83%
Genmab A/S	Outperform Votes 161 62.65%	Underperform Votes 96 37.35%

Which has better earnings and valuation, BHVN or GMAB?

Genmab A/S has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven	N/A	N/A	-$408.17M	-$9.35	-4.02
Genmab A/S	$19.84B	0.69	$631.91M	$1.03	20.19

Do analysts prefer BHVN or GMAB?

Biohaven currently has a consensus target price of $63.00, indicating a potential upside of 67.70%. Genmab A/S has a consensus target price of $45.20, indicating a potential upside of 117.31%. Given Genmab A/S's higher probable upside, analysts plainly believe Genmab A/S is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biohaven	0 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	3.07
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is BHVN or GMAB more profitable?

Genmab A/S has a net margin of 23.49% compared to Biohaven's net margin of 0.00%. Genmab A/S's return on equity of 14.64% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biohaven	N/A	-225.12%	-158.89%
Genmab A/S	23.49%	14.64%	12.37%

Does the media refer more to BHVN or GMAB?

In the previous week, Biohaven and Biohaven both had 7 articles in the media. Genmab A/S's average media sentiment score of 0.96 beat Biohaven's score of 0.01 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biohaven	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Biohaven on 9 of the 17 factors compared between the two stocks.